A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women

Trial Profile

A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Hepatitis B vaccine recombinant; Human papillomavirus vaccine
  • Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Hepatitis B; Human papillomavirus infections; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE-I
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 20 Jul 2010 Results of a pooled analysis of the FUTURE-I and -II trials have been published in the British Medical Journal.
    • 17 Dec 2009 Actual number of patients changed from 5700 to 5759 as reported by ClinicalTrials.gov NCT00092521.
    • 14 Jul 2009 Actual number of patients changed from 5455 to 5700 as reported by ClinicalTrials.gov NCT00092521.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top